Cumberland Pharmaceuticals Files 8-K
Ticker: CPIX · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1087294
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K, but no juicy details yet.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on February 14, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details about the nature of the "Other Events" beyond its classification.
Why It Matters
This filing indicates a regulatory update from Cumberland Pharmaceuticals Inc., but lacks specific details on the events or financial information being reported.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no immediate negative or positive financial implications disclosed.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC (company) — Registrant
- February 14, 2025 (date) — Date of Report
FAQ
What specific "Other Events" are being reported by Cumberland Pharmaceuticals Inc. in this 8-K filing?
The filing does not specify the nature of the "Other Events" beyond their classification as such.
Are there any financial statements or exhibits included with this 8-K filing?
Yes, the filing indicates that "Financial Statements and Exhibits" are included as part of the report.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is February 14, 2025.
What is Cumberland Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is the SIC code for Cumberland Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Cumberland Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-02-14 16:25:51
Key Financial Figures
- $10,000,000 — ith H.C. Wainwright & Co., LLC to up to $10,000,000 and filed a prospectus supplement (the
Filing Documents
- cpix-20250214.htm (8-K) — 29KB
- exhibit51stickerprosuppopi.htm (EX-5.1) — 16KB
- image_0.jpg (GRAPHIC) — 37KB
- 0001628280-25-005744.txt ( ) — 223KB
- cpix-20250214.xsd (EX-101.SCH) — 2KB
- cpix-20250214_lab.xml (EX-101.LAB) — 21KB
- cpix-20250214_pre.xml (EX-101.PRE) — 12KB
- cpix-20250214_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On February 14, 2025, Cumberland Pharmaceuticals, Inc. (the "Company") increased the maximum aggregate offering price of the shares of the Company's common stock, no par value per share (the "Common Stock") issuable under the Sales Agreement, dated March 20, 2024 (the "Sales Agreement") with H.C. Wainwright & Co., LLC to up to $10,000,000 and filed a prospectus supplement (the "Current Prospectus Supplement") under the Sales Agreement for an aggregate offering amount of up to $10,000,000. The Current Prospectus Supplement amends and supplements the information in the prospectus supplement, dated March 20, 2024 (the "Prior Prospectus Supplement"), filed as part of the Company's registration statement on Form S-3 (File No. 333-276052). The Current Prospectus Supplement should be read in conjunction with the Prior Prospectus Supplement, except to the extent that the information therein amends or supersedes the information contained in the Prior Prospectus Supplement. The Current Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus Supplement and any further amendments or supplements thereto. A copy of the legal opinion as to the legality of the $10,000,000 of shares of Common Stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC 23.1 Consent of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC (contained in Exhibit 5.1 above). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: February 14, 2025 By: /s/ A.J. Kazimi A.J. Kazimi Chief Executive Officer